Company Profile Corporate Governance 2009 Annual Meeting Stock Information SEC Filings Analyst Coverage Press Releases Annual Reports Investor Calendar Clinical and Scientific Calendar Board of Directors Senior Management Investor Contact Information Request Form Investor FAQ E-mail Alerts Policy on Rumors Company Profile More >> Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the central nervous system by selectively targeting neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. More than 20 years of focused research and investment make us a leader in the NNR field. More >> Stock Quote TRGT (Common Stock) Exchange NASDAQ (US Dollar) Price $19.10 Change (%)   0.05 (0.26%) Volume 29,567 Data as of 03/12/10 2:11 p.m. ET Minimum 20 minute delay Refresh quote Recent News More News >> Date Title   02/11/10 Targacept Reports Fourth Quarter and 2009 Financial Results 02/08/10 Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease 02/04/10 Targacept to Report Fourth Quarter and 2009 Financial Results on February 11, 2010 Contact Information Alan Musso Vice President and Chief Financial Officer Phone: (336) 480-2186 Fax: (336) 480-2103 E-mail: alan.musso@targacept.com Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ©2010 Targacept, Inc.Terms of Use HomeDirectionsContactSite Map Go